Ph I/IIa Trial Data With Oral Panretin

- In a Phase I/IIa trial, patients with newly-diagnosed or relapsedacute promyelocytic leukemia who were treated with Allergan Ligand Retinoid Therapeutics' oral Panretin (9-cis-retinoic acid), attained complete, durable remission, says the company. Four of the five newly-diagnosed patients achieved complete remission, as did four of the 12 relapsed patients. A Phase III trial of Panretin topical gel was recently halted on positive results in AIDS-related Kaposi's sarcoma (Marketletter September 1).